Obirikorang Christian, Issahaku Razak Gyesi, Osakunor Derick Nii Mensah, Osei-Yeboah James
Department of Molecular Medicine, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Department of Molecular Medicine, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Medical Laboratory Department, Tamale Teaching Hospital, Tamale, Ghana.
AIDS Res Treat. 2016;2016:1623094. doi: 10.1155/2016/1623094. Epub 2016 Mar 22.
Aim. We determined the prevalence of anaemia and evaluated markers of iron homeostasis in a cohort of HIV patients. Methods. A comparative cross-sectional study on 319 participants was carried out at the Tamale Teaching Hospital from July 2013 to December 2013, 219 patients on HAART (designated On-HAART) and 100 HAART-naive patients. Data gathered include sociodemography, clinical history, and selected laboratory assays. Results. Prevalence of anaemia was 23.8%. On-HAART participants had higher CD4/CD3 lymphocyte counts, Hb, HCT/PCV, MCV, MCH, iron, ferritin, and TSAT (P < 0.05). Hb, iron, ferritin, and TSAT decreased from grade 1 to grade 3 anaemia and CD4/CD3 lymphocyte count was lowest in grade 3 anaemia (P < 0.05). Iron (P = 0.0072) decreased with disease severity whilst transferrin (P = 0.0143) and TIBC (P = 0.0143) increased with disease severity. Seventy-six (23.8%) participants fulfilled the criteria for anaemia, 86 (26.9%) for iron deficiency, 41 (12.8%) for iron deficiency anaemia, and 17 (5.3%) for iron overload. The frequency of anaemia was higher amongst participants not on HAART (OR 2.6 for grade 1 anaemia; OR 3.0 for grade 3 anaemia). Conclusion. In this study population, HIV-associated anaemia is common and is related to HAART status and disease progression. HIV itself is the most important cause of anaemia and treatment of HIV should be a priority compared to iron supplementation.
目的。我们确定了一组HIV患者中贫血的患病率，并评估了铁稳态指标。方法。2013年7月至2013年12月在塔马利教学医院对319名参与者进行了一项比较横断面研究，其中219名接受高效抗逆转录病毒治疗（HAART）的患者（指定为HAART治疗组）和100名未接受HAART治疗的患者。收集的数据包括社会人口统计学、临床病史和选定的实验室检测。结果。贫血患病率为23.8%。接受HAART治疗的参与者CD4/CD3淋巴细胞计数、血红蛋白（Hb）、血细胞比容/红细胞压积（HCT/PCV）、平均红细胞体积（MCV）、平均红细胞血红蛋白含量（MCH）、铁、铁蛋白和转铁蛋白饱和度（TSAT）更高（P<0.05）。从1级贫血到3级贫血，Hb、铁、铁蛋白和TSAT降低，3级贫血时CD4/CD3淋巴细胞计数最低（P<0.05）。铁（P=0.0072）随疾病严重程度降低而降低，而转铁蛋白（P=0.0143）和总铁结合力（TIBC，P=0.0143）随疾病严重程度增加而增加。76名（23.8%）参与者符合贫血标准，86名（26.9%）符合缺铁标准，41名（12.8%）符合缺铁性贫血标准，17名（5.3%）符合铁过载标准。未接受HAART治疗的参与者中贫血发生率更高（1级贫血的比值比为2.6；3级贫血的比值比为3.0）。结论。在本研究人群中，HIV相关贫血很常见，且与HAART治疗状态和疾病进展有关。HIV本身是贫血的最重要原因，与补充铁剂相比，治疗HIV应作为优先事项。
